Four-Pronged attack tested against stubborn blood cancer
NCT ID NCT07150091
Summary
This early-stage study is testing the safety and finding the right dose of a four-drug combination for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if combining these medications can better control the cancer. Researchers will enroll about 20 participants to monitor side effects and see how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Hamburg, 22083, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
Conditions
Explore the condition pages connected to this study.